Bristol Myers Squibb Company $BMY Stake Lifted by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 18.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,232,919 shares of the biopharmaceutical company’s stock after acquiring an additional 503,930 shares during the period. Bristol Myers Squibb makes up approximately 0.8% of AustralianSuper Pty Ltd’s investment portfolio, making the stock its 28th biggest position. AustralianSuper Pty Ltd’s holdings in Bristol Myers Squibb were worth $149,652,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Brighton Jones LLC lifted its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. GAMMA Investing LLC lifted its stake in Bristol Myers Squibb by 18.8% during the first quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock valued at $2,420,000 after purchasing an additional 6,267 shares during the last quarter. Guardian Asset Advisors LLC acquired a new stake in Bristol Myers Squibb during the first quarter valued at approximately $204,000. Aljian Capital Management LLC lifted its stake in Bristol Myers Squibb by 29.4% during the first quarter. Aljian Capital Management LLC now owns 20,866 shares of the biopharmaceutical company’s stock valued at $1,273,000 after purchasing an additional 4,745 shares during the last quarter. Finally, Sovran Advisors LLC lifted its stake in Bristol Myers Squibb by 39.4% during the first quarter. Sovran Advisors LLC now owns 6,839 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 1,932 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol Myers Squibb Stock Up 0.0%

BMY stock opened at $43.84 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The company has a market cap of $89.24 billion, a price-to-earnings ratio of 17.68, a PEG ratio of 2.29 and a beta of 0.33. The company has a 50 day moving average of $45.75 and a two-hundred day moving average of $47.05.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the prior year, the firm earned $2.07 EPS. The company’s revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. Bristol Myers Squibb’s dividend payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on BMY shares. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $57.23.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.